Real‐world evidence from the non‐interventional, prospective, German multicentre PERSIST study of patients with psoriasis after 1 year of treatment with guselkumab
Sign Up to like & getrecommendations! Published in 2022 at "Journal of the European Academy of Dermatology and Venereology"
DOI: 10.1111/jdv.18218
Abstract: PERSIST was a prospective, non‐interventional, long‐term, German multicentre study of patients with moderate‐to‐severe psoriasis receiving guselkumab, an approved monoclonal antibody that binds to the p19 subunit of interleukin (IL)‐23, in a real‐world setting. read more here.
Keywords: study patients; non interventional; german multicentre; persist ... See more keywords